TY - JOUR

T1 - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns

AU - Egerup, Pia

AU - Fich Olsen, Line

AU - Christiansen, Ann-Marie Hellerung

AU - Westergaard, David

AU - Severinsen, Elin Rosenbek

AU - Hviid, Kathrine Vauvert Römmelmayer

AU - Kolte, Astrid Marie

AU - Boje, Amalie Dyhrberg

AU - Bertelsen, Marie-Louise Mathilde Friis

AU - Prætorius, Lisbeth

AU - Zedeler, Anne

AU - Nielsen, Josefine Reinhardt

AU - Bang, Didi

AU - Berntsen, Sine

AU - Ethelberg-Findsen, Jeppe

AU - Storm, Ditte Marie

AU - Bello-Rodríguez, Judith

AU - Ingham, Andreas

AU - Ollé-López, Joaquim

AU - Hoffmann, Eva R

AU - Wilken-Jensen, Charlotte

AU - Krebs, Lone

AU - Jørgensen, Finn Stener

AU - Westh, Henrik

AU - Jørgensen, Henrik Løvendahl

AU - la Cour Freiesleben, Nina

AU - Nielsen, Henriette Svarre

N1 - Copyright © 2020 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - OBJECTIVE: To investigate the frequency of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in parturient women, their partners, and their newborns and the association of such antibodies with obstetric and neonatal outcomes.METHODS: From April 4 to July 3, 2020, in a single university hospital in Denmark, all parturient women and their partners were invited to participate in the study, along with their newborns. Participating women and partners had a pharyngeal swab and a blood sample taken at admission; immediately after delivery, a blood sample was drawn from the umbilical cord. The swabs were analyzed for SARS-CoV-2 RNA by polymerase chain reaction, and the blood samples were analyzed for SARS-CoV-2 antibodies. Full medical history and obstetric and neonatal information were available.RESULTS: A total of 1,313 parturient women (72.5.% of all women admitted for delivery at the hospital in the study period), 1,188 partners, and 1,206 newborns participated in the study. The adjusted serologic prevalence was 2.6% in women and 3.5% in partners. Seventeen newborns had SARS-CoV-2 immunoglobulin G (IgG) antibodies, and none had immunoglobulin M antibodies. No associations between SARS-CoV-2 antibodies and obstetric or neonatal complications were found (eg, preterm birth, preeclampsia, cesarean delivery, Apgar score, low birth weight, umbilical arterial pH, need for continuous positive airway pressure, or neonatal admission), but statistical power to detect such differences was low. Full serologic data from 1,051 families showed an absolute risk of maternal infection of 39% if the partner had antibodies.CONCLUSION: We found no association between SARS-CoV-2 infection and obstetric or neonatal complications. Sixty-seven percent of newborns delivered by mothers with antibodies had SARS-CoV-2 IgG antibodies. A limitation of our study is that we lacked statistical power to detect small but potentially meaningful differences between those with and without evidence of infection.

AB - OBJECTIVE: To investigate the frequency of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in parturient women, their partners, and their newborns and the association of such antibodies with obstetric and neonatal outcomes.METHODS: From April 4 to July 3, 2020, in a single university hospital in Denmark, all parturient women and their partners were invited to participate in the study, along with their newborns. Participating women and partners had a pharyngeal swab and a blood sample taken at admission; immediately after delivery, a blood sample was drawn from the umbilical cord. The swabs were analyzed for SARS-CoV-2 RNA by polymerase chain reaction, and the blood samples were analyzed for SARS-CoV-2 antibodies. Full medical history and obstetric and neonatal information were available.RESULTS: A total of 1,313 parturient women (72.5.% of all women admitted for delivery at the hospital in the study period), 1,188 partners, and 1,206 newborns participated in the study. The adjusted serologic prevalence was 2.6% in women and 3.5% in partners. Seventeen newborns had SARS-CoV-2 immunoglobulin G (IgG) antibodies, and none had immunoglobulin M antibodies. No associations between SARS-CoV-2 antibodies and obstetric or neonatal complications were found (eg, preterm birth, preeclampsia, cesarean delivery, Apgar score, low birth weight, umbilical arterial pH, need for continuous positive airway pressure, or neonatal admission), but statistical power to detect such differences was low. Full serologic data from 1,051 families showed an absolute risk of maternal infection of 39% if the partner had antibodies.CONCLUSION: We found no association between SARS-CoV-2 infection and obstetric or neonatal complications. Sixty-seven percent of newborns delivered by mothers with antibodies had SARS-CoV-2 IgG antibodies. A limitation of our study is that we lacked statistical power to detect small but potentially meaningful differences between those with and without evidence of infection.

KW - Adult

KW - Antibodies, Viral/blood

KW - COVID-19 Testing/statistics & numerical data

KW - COVID-19/blood

KW - Denmark/epidemiology

KW - Female

KW - Hospitalization

KW - Hospitals, University

KW - Humans

KW - Immunoglobulin G/blood

KW - Immunoglobulin M/blood

KW - Infant, Newborn/blood

KW - Infectious Disease Transmission, Vertical/statistics & numerical data

KW - Male

KW - Obstetric Labor Complications/epidemiology

KW - Pregnancy

KW - Pregnancy Complications, Infectious/epidemiology

KW - Pregnancy Outcome/epidemiology

KW - Premature Birth/epidemiology

KW - Regression Analysis

KW - Risk Factors

KW - SARS-CoV-2/immunology

KW - Sexual Partners

UR - http://www.scopus.com/inward/record.url?scp=85099427271&partnerID=8YFLogxK

U2 - 10.1097/AOG.0000000000004199

DO - 10.1097/AOG.0000000000004199

M3 - Journal article

C2 - 33116054

VL - 137

SP - 49

EP - 55

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 1

ER -